EGFR and non-small cell lung carcinoma: A new strategy of EGFR-TKI plus antiangiogenic agents [9, 10] supports a hypothesis that combining EGFR-TKI and ginsenoside Rg3 may benefit advanced NSCLC patients harboring EGFR active mutation.